Platelet count, not oxidative stress, may contribute to inadequate platelet inhibition by aspirin

International Journal of Cardiology

Volumn 143, Issue 1, 2010, Pages 43-50

  Lordkipanidzé, Marie ^a,b   Diodati, Jean G ^a,b   Turgeon, Jacques ^a   Schampaert, Erick ^a,b   Palisaitis, Donald A ^a,b   Pharand, Chantal ^a,b  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b HÔPITAL DU SACRÉ COEUR DE MONTRÉAL   (Canada)

Author keywords

Aspirin responsiveness; Coronary artery disease; Oxidative stress; Platelet count

Indexed keywords

8 ISOPROSTANE; ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTILIPEMIC AGENT; ARACHIDONIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; NITRIC ACID DERIVATIVE; 8-EPI-PROSTAGLANDIN F2ALPHA; ANTITHROMBOCYTIC AGENT; PROSTAGLANDIN F2 ALPHA;

ARTICLE; CORONARY ARTERY DISEASE; CORONARY ARTERY OBSTRUCTION; DRUG RESPONSE; ENZYME IMMUNOASSAY; FEMALE; HUMAN; LIGHT TRANSMISSION AGGREGOMETRY; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; OXIDATIVE STRESS; PRIORITY JOURNAL; THROMBOCYTE AGGREGATION; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTE COUNT; THROMBOCYTOPOIESIS; URINALYSIS; URINE LEVEL; AGED; ANALOGS AND DERIVATIVES; CYTOLOGY; DRUG EFFECTS; DRUG RESISTANCE; MIDDLE AGED; PHYSIOLOGY; RISK FACTOR; THROMBOCYTE; THROMBOEMBOLISM; TREATMENT FAILURE; URINE;

AGED; ASPIRIN; BLOOD PLATELETS; CORONARY ARTERY DISEASE; DINOPROST; DRUG RESISTANCE; FEMALE; HUMANS; MALE; MIDDLE AGED; OXIDATIVE STRESS; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET COUNT; RISK FACTORS; THROMBOEMBOLISM; TREATMENT FAILURE;

EID: 77955654079     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijcard.2009.01.037     Document Type: Article

References (53)

1. T. Thom, N. Haase, and W. Rosamond Heart disease and stroke statistics-2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee Circulation 113 2006 e85 e151
2. Antithrombotic Trialists Collaboration Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients BMJ 324 2002 71 86
3. E.H. Awtry, and J. Loscalzo Aspirin Circulation 101 2000 1206 1218
4. M. Lordkipanidzé, C. Pharand, D.A. Palisaitis, and J.G. Diodati Aspirin resistance: truth or dare Pharmacol Ther 112 2006 733 743
5. A.D. Michelson, M. Cattaneo, and J.W. Eikelboom Aspirin resistance: position paper of the Working Group on Aspirin Resistance J Thromb Haemost 3 2005 1309 1311
6. A. Csiszar, G. Stef, P. Pacher, and Z. Ungvari Oxidative stress-induced isoprostane formation may contribute to aspirin resistance in platelets Prostaglandins Leukot Essent Fat Acids 66 2002 557 558
7. F. Cipollone, G. Ciabattoni, and P. Patrignani Oxidant stress and aspirin-insensitive thromboxane biosynthesis in severe unstable angina Circulation 102 2000 1007 1013
8. S. Basu Isoprostanes: novel bioactive products of lipid peroxidation Free Radic Res 38 2004 105 122
9. L.J. Roberts 2nd, and J.D. Morrow Products of the isoprostane pathway: unique bioactive compounds and markers of lipid peroxidation Cell Mol Life Sci 59 2002 808 820
10. R. Kranzhofer, and J. Ruef Aspirin resistance in coronary artery disease is correlated to elevated markers for oxidative stress but not to the expression of cyclooxygenase (COX) 1/2, a novel COX-1 polymorphism or the PlA(1/2) polymorphism Platelets 17 2006 163 169
11. A.D. Michelson Platelet function testing in cardiovascular diseases Circulation 110 2004 e489 e493
12. H. Mani, B. Luxembourg, C. Klaffling, M. Erbe, and E. Lindhoff-Last Use of native or platelet count adjusted platelet rich plasma for platelet aggregation measurements J Clin Pathol 58 2005 747 750
13. J. Burke, W.K. Kraft, and H.E. Greenberg Relationship of arachidonic acid concentration to cyclooxygenase-dependent human platelet aggregation J Clin Pharmacol 43 2003 983 989
14. P.A. Gum, K. Kottke-Marchant, P.A. Welsh, J. White, and E.J. Topol A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease J Am Coll Cardiol 41 2003 961 965 (Pubitemid 36315537)
15. P. Wenaweser, J. Dorffler-Melly, and K. Imboden Stent thrombosis is associated with an impaired response to antiplatelet therapy J Am Coll Cardiol 45 2005 1748 1752
16. G. Davi, A. Falco, and C. Patrono Determinants of F2-isoprostane biosynthesis and inhibition in man Chem Phys Lipids 128 2004 149 163
17. M.M. Hovens, J.D. Snoep, J.C. Eikenboom, J.G. van der Bom, B.J. Mertens, and M.V. Huisman Prevalence of persistent platelet reactivity despite use of aspirin: a systematic review Am Heart J 153 2007 175 181
18. G. Cheng, J. Shan, and G. Xu Relationship between endothelial dysfunction, oxidant stress and aspirin resistance in patients with stable coronary heart disease J Clin Pharm Ther 32 2007 287 292
19. C. Vassalle, L. Petrozzi, N. Botto, M.G. Andreassi, and G.C. Zucchelli Oxidative stress and its association with coronary artery disease and different atherogenic risk factors J Intern Med 256 2004 308 315
20. J. Helmersson, and S. Basu F2-isoprostane excretion rate and diurnal variation in human urine Prostaglandins Leukot Essent Fat Acids 61 1999 203 205
21. J.L. Cracowski, T. Durand, and G. Bessard Isoprostanes as a biomarker of lipid peroxidation in humans: physiology, pharmacology and clinical implications Trends Pharmacol Sci 23 2002 360 366
22. I. Narvaez, J.D. Sagastagoitia, and M. Vacas Prevalence and biologic profile of aspirin resistance in patients with angiographically proven coronary artery disease Thromb Res 120 2007 671 677
23. I.A. Reilly, and G.A. FitzGerald Inhibition of thromboxane formation in vivo and ex vivo: implications for therapy with platelet inhibitory drugs Blood 69 1987 180 186
24. A.O. Maree, R.J. Curtin, and M. Dooley Platelet response to low-dose enteric-coated aspirin in patients with stable cardiovascular disease J Am Coll Cardiol 46 2005 1258 1263
25. A.O. Maree, and D.J. Fitzgerald Variable platelet response to aspirin and clopidogrel in atherothrombotic disease Circulation 115 2007 2196 2207
26. C. Patrono, G. Ciabattoni, and P. Patrignani Clinical pharmacology of platelet cyclooxygenase inhibition Circulation 72 1985 1177 1184
27. G.A. FitzGerald, J.A. Oates, and J. Hawiger Endogenous biosynthesis of prostacyclin and thromboxane and platelet function during chronic administration of aspirin in man J Clin Invest 71 1983 676 688
28. P. Patrignani, P. Filabozzi, and C. Patrono Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects J Clin Invest 69 1982 1366 1372
29. B.B. Weksler, S.B. Pett, and D. Alonso Differential inhibition by aspirin of vascular and platelet prostaglandin synthesis in atherosclerotic patients N Engl J Med 308 1983 800 805
30. K. Kaushansky The molecular mechanisms that control thrombopoiesis J Clin Invest 115 2005 3339 3347
31. S. Guthikonda, E.I. Lev, and R. Patel Reticulated platelets and uninhibited COX-1 and COX-2 decrease the antiplatelet effects of aspirin J Thromb Haemost 5 2007 490 496
32. M.P. Turakhia, S.A. Murphy, and T.L. Pinto Association of platelet count with residual thrombus in the myocardial infarct-related coronary artery among patients treated with fibrinolytic therapy for ST-segment elevation acute myocardial infarction Am J Cardiol 94 2004 1406 1410
33. W.H. Chen, P.Y. Lee, W. Ng, H.F. Tse, and C.P. Lau Aspirin resistance is associated with a high incidence of myonecrosis after non-urgent percutaneous coronary intervention despite clopidogrel pretreatment J Am Coll Cardiol 43 2004 1122 1126
34. J.W. Eikelboom, J. Hirsh, J.I. Weitz, M. Johnston, Q. Yi, and S. Yusuf Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events Circulation 105 2002 1650 1655
35. E. Nikolsky, C.L. Grines, and D.A. Cox Impact of baseline platelet count in patients undergoing primary percutaneous coronary intervention in acute myocardial infarction (from the CADILLAC trial) Am J Cardiol 99 2007 1055 1061
36. R. Iijima, G. Ndrepepa, and J. Mehilli Relationship between platelet count and 30-day clinical outcomes after percutaneous coronary interventions. Pooled analysis of four ISAR trials Thromb Haemost 98 2007 852 857
37. S.G. Albert, B.I. Hasnain, D.G. Ritter, J.H. Joist, and A.D. Mooradian Aspirin sensitivity of platelet aggregation in diabetes mellitus Diabetes Res Clin Pract 70 2005 195 199
38. L. Christiaens, L. Macchi, and D. Herpin Resistance to aspirin in vitro at rest and during exercise in patients with angiographically proven coronary artery disease Thromb Res 108 2003 115 119
39. M. Friend, I. Vucenik, and M. Miller Research pointers: platelet responsiveness to aspirin in patients with hyperlipidaemia BMJ 326 2003 82 83
40. P.A. Gum, K. Kottke-Marchant, and E.D. Poggio Profile and prevalence of aspirin resistance in patients with cardiovascular disease Am J Cardiol 88 2001 230 235
41. M. Tamminen, R. Lassila, J. Westerbacka, S. Vehkavaara, and H. Yki-Jarvinen Obesity is associated with impaired platelet-inhibitory effect of acetylsalicylic acid in nondiabetic subjects Int J Obes Relat Metab Disord 27 2003 907 911
42. P.Y. Lee, W.H. Chen, and W. Ng Low-dose aspirin increases aspirin resistance in patients with coronary artery disease Am J Med 118 2005 723 727
43. K. Andersen, M. Hurlen, H. Arnesen, and I. Seljeflot Aspirin non-responsiveness as measured by PFA-100 in patients with coronary artery disease Thromb Res 108 2003 37 42
44. D. Cox, A.O. Maree, M. Dooley, R. Conroy, M.F. Byrne, and D.J. Fitzgerald Effect of enteric coating on antiplatelet activity of low-dose aspirin in healthy volunteers Stroke 37 2006 2153 2158
45. T. Goodman, A. Ferro, and P. Sharma Pharmacogenetics of aspirin resistance: a comprehensive systematic review Br J Clin Pharmacol 66 2008 222 232
46. A.O. Maree, R.J. Curtin, and A. Chubb Cyclooxygenase-1 haplotype modulates platelet response to aspirin J Thromb Haemost 3 2005 2340 2345
47. S.L. Hetherington, R.K. Singh, D. Lodwick, J.R. Thompson, A.H. Goodall, and N.J. Samani Dimorphism in the P2Y1 ADP receptor gene is associated with increased platelet activation response to ADP Arterioscler Thromb Vasc Biol 25 2005 252 257
48. B.K. Jefferson, J.H. Foster, and J.J. McCarthy Aspirin resistance and a single gene Am J Cardiol 95 2005 805 808
49. G. Andrioli, P. Minuz, and P. Solero Defective platelet response to arachidonic acid and thromboxane A(2) in subjects with Pl(A2) polymorphism of beta(3) subunit (glycoprotein IIIa) Br J Haematol 110 2000 911 918
50. L. Macchi, L. Christiaens, and S. Brabant Resistance in vitro to low-dose aspirin is associated with platelet PlA1 (GP IIIa) polymorphism but not with C807T(GP Ia/IIa) and C-5T kozak (GP Ib[alpha]) polymorphisms J Am Coll Cardiol 42 2003 1115 1119
51. K.A. Schwartz, D.E. Schwartz, K. Ghosheh, M.J. Reeves, K. Barber, and A. DeFranco Compliance as a critical consideration in patients who appear to be resistant to aspirin after healing of myocardial infarction Am J Cardiol 95 2005 973 975
52. C. Perneby, N.H. Wallen, C. Rooney, D. Fitzgerald, and P. Hjemdahl Dose- and time-dependent antiplatelet effects of aspirin Thromb Haemost 95 2006 652 658
53. A.J. Coats Ethical authorship and publishing Int J Cardiol 131 2009 149 150